ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 544,04
-0,55%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Plus Therapeutics Inc (PSTV)

  7. Plus Therapeutics Inc (PSTV) Actualités

PSTV Plus Therapeutics Inc

1,80
0,00 (0,00%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Plus Therapeutics Inc PSTV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 1,80 06:00:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,80 1,80 1,84 1,80 1,80
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
22/4/202413:00GLOBEPlus Therapeutics Receives $3 Million Award Recommendation..
08/3/202422:30EDGAR2Form S-1/A - General form for registration of securities..
05/3/202422:04EDGAR2Form 8-K - Current report
05/3/202422:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202400:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202400:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202323:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202322:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
22/11/202322:08EDGAR2Form S-1 - General form for registration of securities under..
21/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
20/11/202313:01EDGAR2Form 8-K - Current report
17/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202321:55EDGAR2Form 8-K - Current report
31/10/202321:06EDGAR2Form 8-K - Current report
31/10/202321:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/9/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202313:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202313:00GLOBEPlus Therapeutics Receives $1.9 Million Advance Payment from..
08/9/202313:00GLOBEPlus Therapeutics Enters into License Agreement for..
05/9/202313:00GLOBEPlus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a..
30/8/202313:00GLOBEPlus Therapeutics to Present at the H.C. Wainwright 25th..
21/8/202312:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202322:12EDGAR2Form 8-K - Current report
14/8/202322:05GLOBEPlus Therapeutics Reports Second Quarter 2023 Financial..
14/8/202322:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202312:30GLOBEPlus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at..
09/8/202313:55EDGAR2Form S-1 - General form for registration of securities under..
08/8/202322:05GLOBEPlus Therapeutics to Announce Second Quarter 2023 Financial..
08/8/202317:22GLOBEPlus Therapeutics Announces Key Opinion Leader Roundtable on..
03/8/202313:00GLOBEPlus Therapeutics to Present at the Canaccord Genuity 43rd..
27/7/202322:05GLOBEPlus Therapeutics Strengthens Clinical Program with the..
27/7/202313:00GLOBEPlus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer..
13/7/202313:00GLOBEPlus Therapeutics to Present at the 2nd Annual Targeted..
29/6/202313:00GLOBEPlus Therapeutics Reports Positive Interim Updates from Two..
14/6/202313:00GLOBEPlus Therapeutics to Participate in the 2023 Healthcare..
08/6/202313:00GLOBEPlus Therapeutics Announces Participation at Upcoming SNO..
01/6/202313:00GLOBEPlus Therapeutics Provides Company Update Today
30/5/202313:00GLOBEPlus Therapeutics Announces Topline Results from Recurrent..
25/5/202313:00GLOBEPlus Therapeutics to Present at the 2023 Virtual June..
16/5/202313:00GLOBEPlus Therapeutics Regains Compliance with Nasdaq Listing..
12/5/202313:00GLOBEPlus Therapeutics to Present in EndBrainCancer Initiative..

Dernières Valeurs Consultées

NASDAQ
PSTV
Plus Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés